Cargando…
Primary Hyperparathyroidism: A Narrative Review of Diagnosis and Medical Management
Primary hyperparathyroidism (PHPT) is the most common cause of hypercalcemia in the outpatient setting. Symptomatic presentation includes non-specific signs and symptoms of hypercalcemia, skeletal fragility, nephrolithiasis and nephrocalcinosis. The majority of individuals present at an asymptomatic...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068862/ https://www.ncbi.nlm.nih.gov/pubmed/33918966 http://dx.doi.org/10.3390/jcm10081604 |
_version_ | 1783683102143414272 |
---|---|
author | Dandurand, Karel Ali, Dalal S. Khan, Aliya A. |
author_facet | Dandurand, Karel Ali, Dalal S. Khan, Aliya A. |
author_sort | Dandurand, Karel |
collection | PubMed |
description | Primary hyperparathyroidism (PHPT) is the most common cause of hypercalcemia in the outpatient setting. Symptomatic presentation includes non-specific signs and symptoms of hypercalcemia, skeletal fragility, nephrolithiasis and nephrocalcinosis. The majority of individuals present at an asymptomatic stage following routine biochemical screening, without any signs or symptoms of calcium or parathyroid hormone (PTH) excess or target organ damage. Indications for surgery have recently been revised as published in recent guidelines and consensus statements. Parathyroidectomy is advised in patients younger than 50 years old and in the presence of either significant hypercalcemia, impaired renal function, renal stones or osteoporosis. Surgery is always appropriate in suitable surgical candidates, however, medical management may be considered in those with mild asymptomatic disease, contraindications to surgery or failed previous surgical intervention. We summarized the optimal medical interventions available in the care of PHPT patients not undergoing parathyroidectomy. Calcium and vitamin D intake should be optimized. Antiresorptive therapy may be used for skeletal protection in patients with an increased fracture risk. Cinacalcet, a calcimimetic agent, has been shown to effectively lower serum calcium and PTH levels. The effect of medical treatment on the reduction in fracture risk is unknown and should be the focus of future research. |
format | Online Article Text |
id | pubmed-8068862 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80688622021-04-26 Primary Hyperparathyroidism: A Narrative Review of Diagnosis and Medical Management Dandurand, Karel Ali, Dalal S. Khan, Aliya A. J Clin Med Review Primary hyperparathyroidism (PHPT) is the most common cause of hypercalcemia in the outpatient setting. Symptomatic presentation includes non-specific signs and symptoms of hypercalcemia, skeletal fragility, nephrolithiasis and nephrocalcinosis. The majority of individuals present at an asymptomatic stage following routine biochemical screening, without any signs or symptoms of calcium or parathyroid hormone (PTH) excess or target organ damage. Indications for surgery have recently been revised as published in recent guidelines and consensus statements. Parathyroidectomy is advised in patients younger than 50 years old and in the presence of either significant hypercalcemia, impaired renal function, renal stones or osteoporosis. Surgery is always appropriate in suitable surgical candidates, however, medical management may be considered in those with mild asymptomatic disease, contraindications to surgery or failed previous surgical intervention. We summarized the optimal medical interventions available in the care of PHPT patients not undergoing parathyroidectomy. Calcium and vitamin D intake should be optimized. Antiresorptive therapy may be used for skeletal protection in patients with an increased fracture risk. Cinacalcet, a calcimimetic agent, has been shown to effectively lower serum calcium and PTH levels. The effect of medical treatment on the reduction in fracture risk is unknown and should be the focus of future research. MDPI 2021-04-09 /pmc/articles/PMC8068862/ /pubmed/33918966 http://dx.doi.org/10.3390/jcm10081604 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Dandurand, Karel Ali, Dalal S. Khan, Aliya A. Primary Hyperparathyroidism: A Narrative Review of Diagnosis and Medical Management |
title | Primary Hyperparathyroidism: A Narrative Review of Diagnosis and Medical Management |
title_full | Primary Hyperparathyroidism: A Narrative Review of Diagnosis and Medical Management |
title_fullStr | Primary Hyperparathyroidism: A Narrative Review of Diagnosis and Medical Management |
title_full_unstemmed | Primary Hyperparathyroidism: A Narrative Review of Diagnosis and Medical Management |
title_short | Primary Hyperparathyroidism: A Narrative Review of Diagnosis and Medical Management |
title_sort | primary hyperparathyroidism: a narrative review of diagnosis and medical management |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068862/ https://www.ncbi.nlm.nih.gov/pubmed/33918966 http://dx.doi.org/10.3390/jcm10081604 |
work_keys_str_mv | AT dandurandkarel primaryhyperparathyroidismanarrativereviewofdiagnosisandmedicalmanagement AT alidalals primaryhyperparathyroidismanarrativereviewofdiagnosisandmedicalmanagement AT khanaliyaa primaryhyperparathyroidismanarrativereviewofdiagnosisandmedicalmanagement |